Rapt Therapeutics (RAPT) PT Lowered to $23 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
RAPT Therapeutics (RAPT) weakness creates a long-term opportunity - UBS
March 15, 2023 10:01 AM EDTRAPT Therapeutics (NASDAQ: RAPT) shares fell more than 25% on Tuesday, but UBS analyst Eliana Merle believes the stock's weakness creates a long-term opportunity.
On Tuesday, RAPT reported fourth-quarter financials, and UBS spoke with the company's management after the release.
"New from today's release is topline data from the Ph2B of RPT193 in atopic dermatitis is now guided... More
